Congratulations to the Pacira BioSciences, Inc. team for receiving RMAT designation for PCRX-201! This is a great achievement as the RMAT designation was based on strong clinical data in knee #osteoarthritis patients and can expedite the further development of PCRX-201, which was originally developed by GQ Bio Therapeutics. Also, PCRX-201 marks the first-ever #genetherapy to receive RMAT designation – a significant step forward for the high-capacity adenoviral vector technology! https://lnkd.in/dSyb283Y
GQ Bio Therapeutics’ Post
More Relevant Posts
-
Just like football ⚽ (football is nothing without the fans) #clinicaltrials are nothing without the patients 👨🏻🔬🧪 - Ascletis Pharma Inc. has enrolled all 120 patients in its Phase III clinical trial of ASC40 in combination with bevacizumab for the treatment of recurrent glioblastoma (rGBM). - Moleculin Biotech, Inc. has finished enrolling patients in the second phase of its Phase IB/II MB107 clinical trial of Annamycin for treating soft tissue sarcoma (STS) lung metastases. - #YSBiopharma has enrolled the first subject in its comparator-controlled Phase III clinical trial of its PIKA Rabies Vaccine. #patientenrolment
-
-
Medical Oncologist, Researcher – Minsk City Clinical Oncologic Centre, ESO Ambassador
With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers
The last webinar in the #PrecisionOncology series presents ESMO’s new proposal for a classification of tissue-agnostic therapeutics. Secure your place and have your questions answered by international experts. 👉Register now with your ESMO account: 🔗https://ow.ly/G41o50R95Gk Claudia Cardone, Vivek Subbiah, Sewanti Limaye, Benedikt Westphalen, George Pentheroudakis
-
-
We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors
Pleased to share another great presentation from the 10th Annual Oncology Innovation Forum. Medicenna Therapeutics Corp. presentation by Dr. Fahar Merchant, CEO Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum View Here: https://lnkd.in/dBftGMEp Press Release: https://lnkd.in/dR44hYaW #Biotech #InvestorPresentation #SachsForum #Sachs_OIF
Medicenna Therapeutics Corp. @ Sachs_OIF
https://www.youtube.com/
-
Biotech Trading Analyst at Chimera Research Group. Technical Analysis. Consulting & Market analysis of public companies
$MDNAF $MDNA.to We expect to provide a comprehensive data-set on monotherapy from MDNA11 dose-expansion trial And some topline data on combo trial with #Ketruda Finally Sachs shared another great presentation by Dr. Fahar, MDNA's CEO at the 10th Annual Oncology Innovation Forum!
Pleased to share another great presentation from the 10th Annual Oncology Innovation Forum. Medicenna Therapeutics Corp. presentation by Dr. Fahar Merchant, CEO Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum View Here: https://lnkd.in/dBftGMEp Press Release: https://lnkd.in/dR44hYaW #Biotech #InvestorPresentation #SachsForum #Sachs_OIF
Medicenna Therapeutics Corp. @ Sachs_OIF
https://www.youtube.com/
-
Kristi Campoe, PhD, RN, CMSRN, CPHQ, sMBA
Kristi Campoe, PhD, RN, CMSRN, CPHQ, sMBA is an Influencer FemTech Leader | Board Director | Medical Device Expert | Scientist | The BOLD Nurse Coach & Consultant | MEDSURG Nurse Advocate | Author
It's not too late to attend this webinar today - Pharmacogenomics: Transforming Patient Care
Our first webinar of the year is happening tomorrow! Join us from 2 p.m. - 3 p.m. CT as we cover "Pharmacogenomics: Transforming Patient Care". This is a can't-miss session that will explore all about the basics of pharmacogenomics, implications of testing, current uses of pharmacogenomic therapeutics, and more. Register now: https://hubs.la/Q02hTJj30
-
-
🚀 Explore the Special Session: "SPS-04 TB therapeutics: Reflecting on the past and charting the way forward" at 15:00 CET in Room 242A. Join the discussion on groundbreaking approaches to TB treatment. Your engagement contributes to the ongoing quest for innovative therapeutics 🙌 #TB #Research #UnionConf2023
-
-
Today Halia’s CEO David Bearss Ph.D. presented at the 5th Inflammasome Therapeutics Summit in Boston about Halia’s efforts to combat chronic inflammation by inhibiting the inflammasome NLRP3. Dave discussed the early clinical evaluation of Halia’s NLRP3 inhibitor, HT-6184, and its activity as a selective, orally bioavailable, allosteric inhibitor of Nek7/NLRP3. To read more about the results of Halia’s completed Phase 1 clinical trial (NCT05447546), see today’s news release here: https://prn.to/3sV4T4T For more information about the Summit, go to: https://bit.ly/40UyYOI #inflammasome #chronicinflammation #inflammasometherapeuticssummit #NLRP3 #therapeutics
-
-
Join Julie Daves, MSHS, CCRP from DiaMedica Therapeutics, Inc. at the ClinBiz Summit 2023 (Fully Online) on October 23-25, 2023. Have your teams attend fully online with the very affordable group ticket options - It is an event you DO NOT want to miss! For the full agenda topics, speakers and to register visit ( www.clinbizsummit.com ) today. #clinicaloperations #clinicaltrials #clinicalresearch #pharma #oncology #biotech #digitalhealth #investigatorgrants #fairmarketvalue #clinicalstudybudgets #clinicaloutsourcing #clinicalfinancials #clinicalcontracts #decentralizedtrials #decentralizedclinicaltrials #clinicalbudgets #sitepayments #sitebudgets #virtualtrials #investigatorfees #fmv #clinicalstudy #clinbiz #innovation #studystartup #sitecontracts #siteagreements #clinicaltrialagreements #ClinBiz #cta #clinical #sourcing #ClinBizSummit
-
